BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will present a LibiGel clinical update at the 2010 Annual Meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH), being held from February 18-20, 2010 in St. Petersburg, Florida.

“Low Cardiovascular Event Rate in Post-menopausal Women with Increased Cardiac Risk: Findings from the Ongoing Blinded LibiGel (testosterone gel) Cardiovascular and Breast Cancer Safety Study”

Michael C. Snabes, MD, PhD, BioSante’s vice president of clinical development, will give a presentation entitled, “Low Cardiovascular Event Rate in Post-menopausal Women with Increased Cardiac Risk: Findings from the Ongoing Blinded LibiGel (testosterone gel) Cardiovascular and Breast Cancer Safety Study,” on Saturday February 20, 2010.

BioSante is in Phase III development of LibiGel for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women under an FDA approved SPA (Special Protocol Assessment). BioSante is enrolling women in three Phase III clinical studies with a new drug application (NDA) planned for mid-2011. “There still is no FDA approved pharmaceutical product for the treatment of HSDD and it is clear from the extensive off-label use of drugs for HSDD that women need an approved therapy. We believe LibiGel can be first product to market for this unmet medical need.” said Dr. Snabes.

The annual ISSWSH conference brings together physicians, other healthcare providers, researchers, investors and companies in a meeting dealing with all issues related to women’s sexual health including HSDD.